Dynavax (NASDAQ: DVAX) reported Q4 EPS of $0.05, $0.01 better than the analyst estimate of $0.04. Revenue for the quarter came in at $71.1 million versus the consensus estimate of $72.44 million.

GUIDANCE:

Dynavax sees FY2025 revenue of $305-325 million, versus the consensus of $332.4 million.

For earnings history and earnings-related data on Dynavax (DVAX) click here.